Quantification of Plasma 8-Isoprostane by High-Performance Liquid Chromatography with Tandem Mass Spectrometry in a Case-Control Study of Lung Cancer

Aim: 8-iso-prostaglandin F2α is a biomarker of lipid peroxidation, and one of the most commonly used measures of oxidative stress. It is an established biomarker of lung cancer risk. It is commonly measured by enzyme-linked immunosorbent assay. Given its importance, we developed a stable isotope dilution UPLC-tandem mass spectrometric method for the rapid determination of 8-isoprostane in blood. Methods: We tested the discriminatory capability of the method in 49 lung cancer patients, 55 benign lung nodule patients detected by chest X-ray, and 41 patients with chronic obstructive pulmonary disease (COPD) or asthma. Results: Significant differences were found in mean 8-isoprostane levels between the three groups (p = 0.027), and post-hoc tests found higher levels in the lung cancer patients than in patients with benign nodules (p = 0.032) and COPD/asthma (p = 0.014). The receiving operating characteristic area under the curve (AUC) was 0.69 for differentiating the lung cancer group from the benign nodule group, and 0.7 for differentiating from the COPD/asthma group. Conclusions: The UPLC-MS/MS-based method is an efficient analytical tool for measuring 8-isoprostane plasma concentrations. The results suggest exploring its utility as a marker for early lung cancer screening.

[1]  J. Halgunset,et al.  RNA-Integrity and 8-Isoprostane Levels Are Stable in Prostate Tissue Samples Upon Long-Term Storage at -80°C. , 2020, Biopreservation and biobanking.

[2]  N. Ayas,et al.  Obstructive Sleep Apnea and Circulating Biomarkers of Oxidative Stress: A Cross-Sectional Study , 2020, Antioxidants.

[3]  P. Pirina,et al.  Reliability and Usefulness of Different Biomarkers of Oxidative Stress in Chronic Obstructive Pulmonary Disease , 2020, Oxidative medicine and cellular longevity.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  H. Brenner,et al.  Urinary 8‐isoprostane levels and occurrence of lung, colorectal, prostate, breast and overall cancer: Results from a large, population‐based cohort study with 14 years of follow‐up , 2018, Free radical biology & medicine.

[6]  Jian-Min Yuan,et al.  Relationship of the oxidative damage biomarker 8-epi-prostaglandin F2&agr; to risk of lung cancer development in the Shanghai Cohort Study , 2018, Carcinogenesis.

[7]  B. Brunekreef,et al.  Outdoor air pollution, exhaled 8-isoprostane and current asthma in adults: the EGEA study , 2018, European Respiratory Journal.

[8]  L. Deterding,et al.  Elevated plasma 8‐iso‐prostaglandin F2&agr; levels in human smokers originate primarily from enzymatic instead of non‐enzymatic lipid peroxidation , 2018, Free radical biology & medicine.

[9]  S. Jonasson,et al.  8-Isoprostane is an early biomarker for oxidative stress in chlorine-induced acute lung injury. , 2018, Toxicology letters.

[10]  S. London,et al.  Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis , 2017, Redox biology.

[11]  D. Baldwin,et al.  Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management. , 2016, The Lancet. Oncology.

[12]  L. Deterding,et al.  Reinterpreting the best biomarker of oxidative stress: The 8-iso-prostaglandin F2α/prostaglandin F2α ratio shows complex origins of lipid peroxidation biomarkers in animal models. , 2016, Free radical biology & medicine.

[13]  B. Aggarwal,et al.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases , 2016, Experimental biology and medicine.

[14]  B. Penninx,et al.  Sociodemographic and Lifestyle Determinants of Plasma Oxidative Stress Markers 8-OHdG and F2-Isoprostanes and Associations with Metabolic Syndrome , 2016, Oxidative medicine and cellular longevity.

[15]  H. Gunbatar,et al.  Evaluation of Oxidative Damage and Antioxidant Mechanisms in COPD, Lung Cancer, and Obstructive Sleep Apnea Syndrome , 2016, Respiratory Care.

[16]  L. Roberts,et al.  The isoprostanes--25 years later. , 2015, Biochimica et biophysica acta.

[17]  T. Penning,et al.  Human Aldo-Keto Reductases and the Metabolic Activation of Polycyclic Aromatic Hydrocarbons , 2014, Chemical research in toxicology.

[18]  T. Mori,et al.  Minimizing artifactual elevation of lipid peroxidation products (F2-isoprostanes) in plasma during collection and storage. , 2014, Analytical biochemistry.

[19]  E. Barreiro,et al.  Oxidative stress and inflammation in the normal airways and blood of patients with lung cancer and COPD. , 2013, Free radical biology & medicine.

[20]  Chris P. Sarnowski,et al.  Development of a genotyping microarray for studying the role of gene-environment interactions in risk for lung cancer. , 2013, Journal of biomolecular techniques : JBT.

[21]  J. Namieśnik,et al.  LC-MS/MS Determination of Isoprostanes in Plasma Samples Collected from Mice Exposed to Doxorubicin or Tert-Butyl Hydroperoxide , 2013, International journal of molecular sciences.

[22]  D. Tsikas,et al.  Assessment of urinary F(2)-isoprostanes in experimental and clinical studies: mass spectrometry versus ELISA. , 2012, Hypertension.

[23]  B. Halliwell,et al.  Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. , 2010, Antioxidants & redox signaling.

[24]  D. M. Hassel,et al.  Measurement of Urinary F2-Isoprostanes as Markers of in Vivo Lipid Peroxidation: A Comparison of Enzyme Immunoassays with Gas Chromatography–Mass Spectrometry in Domestic Animal Species , 2010, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[25]  B. Henderson,et al.  Association of Plasma Micronutrient Levels and Urinary Isoprostane with Risk of Lung Cancer: The Multiethnic Cohort Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[26]  K. Kostikas,et al.  VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. , 2009, Lung cancer.

[27]  D. Pelclova,et al.  Determination of 8-iso-prostaglandin F(2alpha) in exhaled breath condensate using combination of immunoseparation and LC-ESI-MS/MS. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  D. Christiani,et al.  Urinary 8-Isoprostane and 8-OHdG Concentrations in Boilermakers With Welding Exposure , 2008, Journal of occupational and environmental medicine.

[29]  M. W. Ogden,et al.  Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS1 Published, JLR Papers in Press, April 24, 2007. , 2007, Journal of Lipid Research.

[30]  J. Morrow,et al.  Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. , 2004, Annals of epidemiology.

[31]  P. Montuschi,et al.  Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. , 2004, The Journal of allergy and clinical immunology.

[32]  D. Postma,et al.  Acute effects of cigarette smoke on inflammation and oxidative stress: a review , 2004, Thorax.

[33]  P. Montuschi,et al.  Increased exhaled 8-isoprostane in childhood asthma. , 2003, Chest.

[34]  P. Barnes,et al.  Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD , 2003, Thorax.

[35]  S. Erzurum,et al.  Antioxidant responses to oxidant-mediated lung diseases. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[36]  G. Davı̀,et al.  In vivo lipid peroxidation and platelet activation in cystic fibrosis. , 2000, American journal of respiratory and critical care medicine.

[37]  N. Lazzeri,et al.  Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. , 2000, American journal of respiratory and critical care medicine.

[38]  L. Wood,et al.  Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma , 2000, Lipids.

[39]  L. Wood,et al.  Elevated plasma levels of F2α isoprostane in cystic fibrosis , 1999, Lipids.

[40]  J. Morrow,et al.  Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. , 1999, Analytical biochemistry.

[41]  G. FitzGerald,et al.  Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. , 1998, American journal of respiratory and critical care medicine.

[42]  J. Tkaczyk,et al.  Oxidative stress in the lung tissue--sources of reactive oxygen species and antioxidant defence. , 2007, Prague medical report.

[43]  J. Morrow,et al.  Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. , 1999, Methods in enzymology.